Differential cytokine expression analysis revealed an upregulation of IL-6, IL-8, IL-10, MIP-1α, MIP-1β, and MCP-1 (CCL2) in JX14P-RT TAMs relative to M2 and downregulation of IL-4, IL-13, IL-1β, and IL-1α (Fig. 4C), suggesting that JX14P-RT TAMs have a higher capacity for tumor-promoting inflammation and monocyte recruitment [7, 39]. The gene discussed is CCL2; the disease is neoplasm.